Skip to main content
Premium Trial:

Request an Annual Quote

BioCure Technology to Develop ROR1-Targeted CAR T-Cell Therapy

NEW YORK – BioCure Technology on Monday said it will begin developing a CAR T-cell therapy for chronic lymphocytic leukemia, or CLL, and solid tumors and seek to patent a novel ROR1-targeted CAR T-cell platform.

For several years, BiocurePharm, a subsidiary of the Vancouver-based BioCure Technology, has been advancing CD19-directed CAR T-cell therapies for acute lymphocytic leukemia, or ALL. In December 2020, BioCure announced plans for a Phase I study of its CD19 CAR T-cell therapy in ALL in South Korea and submitted an investigational new drug application to the Korean Ministry of Food and Drug Safety for that study. The company also has several partnerships to study the CD-19 CAR T-cell therapy including one with Pharos Vaccine to evaluate it for leukemia and lymphoma and another deal to study it in combination with Y Biologics' checkpoint inhibitor in solid tumors.

Based on that experience, BioCure has now decided to advance a novel ROR1 CAR T-cell therapy combined with a double specific antibody for CLL and solid tumors, such as ovarian and lung cancers. The decision was driven by the larger market opportunity presented by CLL compared to ALL and the fact that the CLL CAR T-cell therapy market is less crowded than the CD-19 targeted therapy space, the company said in a statement.

BioCure believes that pursing development of its CAR T-cell therapy in the less competitive CLL space will also increase its chances for obtaining patents protecting its ROR1 CAR T-cell therapy platform.

"The company is extremely excited to be focusing its work in the CAR T-cell cancer therapy field targeting CLL and solid tumors, having spent more than three years to arrive at this stage as a result of its previous work in the CD-19 CAR T and biosimilars space," BioCure CEO Sang Mok Lee said in a statement. "With the company developing its own CAR T technologies protected by patents, the company looks forward to driving strong returns for all of its shareholders in the rapidly growing market of CAR T-cell cancer therapy."